Revenue segments as reported by the company.

Cardiovascular

Medical Surgical

Neuroscience

Diabetes

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Amortization of intangible assets

Restructuring charges, net

Certain litigation charges, net

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Medtronic

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Neuroscience Portfolio is made up of cranial and spinal technologies, specialty therapies, and neuromodulation divisions. The Medical Surgical Portfolio is comprised of surgical innovations and respiratory, gastrointestinal, and renal divisions. The Diabetes Group segment offers insulin pumps, continuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Medtronic reports strong Q4 results, anticipates margin pressures for FY '24

MDT reported strong Q4 results with organic revenue growth, but anticipates margin pressures and EPS decline for FY '24. They highlighted successful FDA approvals and expressed confidence in growth opportunities.

Medtronic reports strong Q2 earnings, highlights growth opportunities

Medtronic's Q2 earnings call showcased strong financial performance, with raised full-year guidance. The company emphasized growth in key business segments and highlighted opportunities in insulin-dependent patient solutions and AI-powered solutions. Challenges include delays in PMRI spend and minimal impact of GLP-1s on the business.

Medtronic exceeds Q3 expectations, focuses on growth and transformation

Medtronic's Q3 earnings call highlighted strong performance, raised outlook, and a focus on transformation for sustainable growth. The company is strategically addressing challenges through cost reduction efforts and seizing opportunities in key markets. Medtronic remains committed to driving innovation and maximizing shareholder value.

Medtronic exceeds Q4 expectations, eyes growth in innovative healthcare

Medtronic's Q4 performance showcased strong growth in key segments, with a focus on innovation and market expansion. Despite challenges from inflation and currency impact, the company remains optimistic about future growth opportunities driven by product advancements and strategic acquisitions.

Medtronic reports robust Q1 results, eyes growth amid challenges

Medtronic's Q1 performance showcased strong revenue growth and emphasized innovation across key business segments.
While facing challenges of growth deceleration and margin expansion, the company remains focused on operational efficiencies and market fundamentals.
Opportunities lie in bariatric space growth, ongoing transformation efforts, and advancements in diabetes programs and surgical systems.
Overall, Medtronic's strategic investments in technology, pricing strategies, and procedural trends position it for continued success and market leadership.

Medtronic surpasses revenue expectations, eyes growth in key markets

Medtronic delivered strong Q2 results with revenue growth ahead of expectations and raised full-year guidance. Despite concerns about GLP-1 drugs and the SELECT trial, the company remains optimistic about growth prospects, focusing on key markets and product innovation.

Medtronic reports solid Q3 growth, focuses on innovation and profitability

Medtronic's Q3 earnings call showcased strong financial performance, international market growth, and strategic decisions to drive innovation and profitability. The company's focus on new technologies, portfolio management, and overcoming challenges highlights a path towards sustained growth and earnings leverage. With positive progress in key business segments and a commitment to future profitability, Medtronic is well-positioned for continued success.

Medtronic reports robust Q4 growth, eyes operational efficiency and China

Medtronic's Q4 2024 earnings call highlighted strong revenue growth, new product launches, and a focus on restoring earnings power. The company provided guidance for fiscal year '25, expecting organic revenue growth, operating margin expansion, and non-GAAP diluted EPS. Analyst questions centered on EPS guidance, revenue growth drivers, and operational efficiencies.

Medtronic reports solid Q1 results, raises guidance for fiscal '25

Medtronic's Q1 2025 performance reflects steady revenue growth and increased EPS, driven by strong performances in key business segments and global markets.
The company's focus on innovation, strategic partnerships, and diversified revenue streams positions it well for future growth and market expansion.
While challenges exist in maintaining growth momentum and navigating market complexities, Medtronic's raised guidance and growth expectations signal confidence in its ability to drive top-line growth and restore earnings power.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Medtronic plc (NYSE:MDT ) Q3 2023 Earnings Conference Call February 21, 2023 8:00 AM ET Company Participants Ryan Weispfenning - Investor Relations Geoff Martha - Chairman and Chief Executive Officer Karen Parkhill - Chief Financial Officer Bob White - Executive Vice President and President, Medical Surgical Portfolio Brett Wall - Executive Vice President and President, Neuroscience Portfolio Que Dallara - Executive Vice President and President, Diabetes Operating Unit Sean Salmon - Executive Vice President and President, Cardiovascular Portfolio Conference Call Participants Robbie Marcus - JPMorgan Larry Biegelsen - Wells Fargo Vijay Kumar - Evercore ISI Joanne Wuensch - Citi Matt Miksic - Barclays Cecilia Furlong - Morgan Stanley Shagun Singh - RBC Travis Steed - BofA Rick Wise - Stifel Nicolaus Ryan Weispfenning Good morning. I am Ryan Weispfenning, Vice President and Head of Medtronic Investor Relations.

Medtronic plc (MDT) Q3 2023 Earnings Call Transcript

Hum-drum Medtronic (NYSE: MDT) has seen its shares fall dramatically over the past year due to a massive downdraft in the analysts' sentiment. The downdraft was caused by the peaking of COVID-19 and the tailwind it provided to businesses.

Medtronic Stock, A Bottom Is In Play

Medtronic (MDT) delivered earnings and revenue surprises of 3.17% and 2.76%, respectively, for the quarter ended January 2023. Do the numbers hold clues to what lies ahead for the stock?

Medtronic (MDT) Surpasses Q3 Earnings and Revenue Estimates

Medtronic raised the low end of its earnings outlook on Tuesday after beating quarterly expectations, but MDT stock sank a fraction. The post Medtronic Beats Quarterly Expectations, Tightens 2023 Earnings Outlook appeared first on Investor's Business Daily.

Medtronic Beats Quarterly Expectations, Tightens 2023 Earnings Outlook

"We returned to mid-single digit organic growth as we execute our strategy," CEO Geoff Martha said in a statement.

Medtronic Beat Earnings Expectations. The Stock Is Rising.

Medtronic Plc stock MDT, +0.71% rose in premarket trade Tuesday, after the medical device maker beat fiscal third-quarter consensus estimates. The Dublin-based medical device maker posted net income of $1.222 billion, or 92 cents a share, for the quarter to Jan. 27, down from $1.480 billion, or $1.10 a share, in the year-earlier period.

Medtronic tops third-quarter estimates as revenue boosted by strong cardiovascular and neuroscience portfolios

Delivers top and bottom line ahead of expectations, with strength in Cardiovascular and Neuroscience portfolios DUBLIN , Feb. 21, 2023 /PRNewswire/ -- Medtronic plc (NYSE:MDT) today announced financial results for its third quarter of fiscal year 2023, which ended January 27, 2023. Key Highlights Revenue of $7.7 billion was flat as reported and increased 4.1% organic, ahead of expectations GAAP diluted EPS of $0.92 decreased 16%; non-GAAP diluted EPS of $1.30 decreased 4%, ahead of expectations Company increases FY23 organic revenue growth and EPS outlook "We returned to mid-single digit organic growth as we execute our strategy with urgency.

Medtronic reports third quarter fiscal 2023 financial results

EV-ICD defibrillation lead placed outside of heart and veins, preserving vasculature DUBLIN , Feb. 17, 2023 /PRNewswire/ -- Medtronic plc (NYSE:MDT) has received CE (Conformité Européenne) Mark for the Aurora EV-ICD™ MRI SureScan™ (Extravascular Implantable Cardioverter-Defibrillator) and Epsila EV™ MRI SureScan™ defibrillation lead to treat dangerously fast heart rhythms that can lead to sudden cardiac arrest. The Aurora EV-ICD system provides the life-saving benefits of traditional ICDs while avoiding certain risks because its lead (thin wire) is placed outside the heart and veins.

Medtronic Receives CE Mark for Extravascular Defibrillator System That Treats Abnormal Heart Rhythms

Amgen

Broadcom

Best Buy

Caterpillar

Comcast

CubeSmart

Enterprise Products Partners

Extra Space Storage

Corning

Johnson & Johnson

Lowe's

ManpowerGroup

Trinity Industries

T. Rowe Price Group

Unum

Whirlpool

Finding companies with a high initial yield and rapid dividend growth is difficult. I present my criteria for finding such companies. At present, there are 16 companies meeting my initial screening requirements. Using additional metrics, these are reduced to five.

5 Stocks In The Dividend Growth Sweet Spot

DUBLIN , Feb. 14, 2023 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it will report financial results for its third quarter of fiscal year 2023 on Tuesday, February 21, 2023. A news release will be issued at approximately 5:45 a.m.

Medtronic to announce financial results for its third quarter of fiscal year 2023

In early February 2023, Medtronic PLC (NYSE: MDT) was found guilty of patent infringement regarding Colibri Heart Valve LLC transcatheter aortic valve replacement system (TAVR). While this is certainly troubling for one of the biggest medical technology manufacturers in the world, it may not significantly derail any momentum they have.

Should Medtronic's Recent Colibri Patent Controversy Concern You?

We expect Medtronic stock to trade higher post Q3, with its revenues and earnings likely falling above the street estimates.

Here's What To Expect From Medtronic's Q3

Cisco Systems

Intel

Morgan Stanley

Pfizer

Philip Morris

Truist Financial

U.S. Bancorp

Vanguard High Dividend Yield ETF

There are 12 stocks on my high-yield watchlist for February 2023. The majority of the stocks on my watchlist are undervalued based on dividend yield theory.

High Yield Stock Watchlist - February 2023

Ares Capital

Altria

Annaly Capital

Rithm Capital Corp

Stryker

Inflation and (expected) actions by the Federal Reserve continue to dominate market movements. Markets have started the new year with very solid gains following expectations about a more dovish Federal Reserve and a solid earnings season.

My Dividend Stock Portfolio: New January Record - 100 Holdings With 26 Buys

ISC23: Late-breaking results from STROKE AF study reinforce importance of long-term continuous cardiac monitoring in ischemic stroke patients DUBLIN and DALLAS , Feb. 8, 2023 /PRNewswire/ -- Medtronic (NYSE: MDT) today announced late-breaking clinical data from the STROKE AF clinical study, which showed large and small vessel disease stroke patients had a 10-fold increase in AF detection with the Reveal LINQ™ insertable cardiac monitor (ICM) at three years compared to patients randomized to standard of care who did not receive continuous, long-term monitoring. The latest results, presented today as a late-breaking clinical trial at the American Stroke Association's International Stroke Conference (ISC) 2023, build on the STROKE AF study 12-month primary endpoint results published in JAMA in June 2021.

Medtronic LINQ Insertable Cardiac Monitor detects 10 times more atrial fibrillation in ischemic stroke patients at three years compared to standard of care

Exact Sciences

Integra LifeSciences Holdings

MedTech companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how EXAS, MDT and IART are poised ahead of their earnings releases.

3 MedTech Stocks Likely to Beat Estimates This Earnings Season

Medtronic has underperformed the market considerably over the last seven years. The company realized that it's not working and initiated a turnaround strategy.

Medtronic: A Turnaround In 4 Steps

Cardinal Health

Canadian Imperial Bank of Commerce

Fulton Financial

Genuine Parts

Huntington Bancshares

Iron Mountain

Illinois Tool Works

Leggett & Platt

National Grid

Realty Income Corp

Paramount Global

PepsiCo

TotalEnergies SE

We received $736.32 in January dividend income! This represents an 18.46% dividend increase compared to last year. The strong dividend income growth is great! That is exactly how you want to start the year off. Our dividend income grew nearly $115 from January 2022.

Bert's January 2023 Dividend Income Summary

Abbott Labs

You can bet the farm on these companies' dividends.

2 Beaten-Down Stocks With Stable Dividends to Buy In 2023

Medtronic is working through top-line headwinds. The company actually stands to benefit from incremental top-line and EPS growth over the long term.

Buying The Medtronic Turnaround Story

Fastenal

Restaurant Brands

Texas Instruments

Verizon

I present my top 10 High Yield dividend stocks that are poised to offer strong future returns. The annualized rate of return for this watchlist is 16.31% over the past 27 months.

My Top 10 High Yield Dividend Stocks For February 2023

News for Medtronic Stock (MDT)